<PAGE> 1
Form 8-K
CURRENT REPORT
Pursuant to Section 13 of 15 (d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2000
Hemispherx Biopharma, Inc.
----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 027072 52-0845822
-------- ------- ------------------
State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification No.)
incorporation)
1617 JFK Blvd, #660, Philadelphia, Pennsylvania 19104
----------------------------------------------- ------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (215) 988-0080
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
Item 4. Changes in Registrant's Certifying Accountant.
On June 5, 2000, Registrant engaged the services of BDO Seidman,
LLP as the Registrant's Independent Accountants. As the Independent
Accountants, BDO Seidman, LLP will audit the Consolidated Financial
Statements and provide other professional services as may be required
by the Registrant.
The Registrant's Board of Directors, with the approval of
Registrant's audit committee, authorized the Company to retain the services
of BDO Seidman, LLP.
Incorporated by reference are Form 8-Ks filed by the Registrant
with the Securities and Exchange Commission on May 10, 2000, and as amended
on May 18, 2000, to include the response of former Registrant's Independent
Accountants.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
HEMISPHERX BIOPHARMA, INC.
Dated: June 6, 2000 By: / s / W. A. Carter, M.D.
----------------------------
W. A. Carter, M.D.
Chairman/CEO/President
